0001193125-26-383838 Sample Contracts
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 2nd day of August, 2023, by and among ADARx Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
YING HUANG, PH.D. Dr. Huang:Board Membership Agreement • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations
We are delighted that you have agreed to join the Board of Directors (the “Board”) of ADARX PHARMACEUTICALS, INC. (the “Company”). This letter sets forth the agreement between you and the Company regarding your Board membership (the “Agreement”):
Collaboration and License Option Agreement Between ADARx Pharmaceuticals, Inc. and The Puerto Rico Branch of AbbVie Biotechnology Ltd Dated as of May 9, 2025Collaboration and License Option Agreement • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Collaboration and License Option Agreement (this “Agreement”) is made and entered into as of May 9, 2025 (the “Effective Date”) by and between ADARx Pharmaceuticals, Inc., a Delaware corporation (“ADARx”), and the Puerto Rico branch of AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”). ADARx and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LEASE AGREEMENTLease Agreement • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 15th day of September, 2020, between ARE-SD REGION NO. 31, LLC, a Delaware limited liability company (“Landlord”), and ADARx PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Separation Agreement and Release (“Agreement”) is made by and between Ajim Tamboli (“Employee”) and ADARx Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement is dated as of _________, 20__ (this “Agreement”) and is between ADARx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).
ADARX PHARMACEUTICALS, INC.Offer of Employment • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations
ADARx Pharmaceuticals, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Chief Financial Officer on the terms and conditions set forth in this letter agreement (the “Agreement”). You will be reporting to President and Chief Executive Officer of the Company, Dr. Zhen Li. You will work at the Company’s offices located at 5871 Oberlin Drive, San Diego, CA 92121.